Mice were then treated with CAR-T cells overexpressing CXCR1 or CXCR2, which led to significant tumor regression and appeared to demonstrate a synergy between radiotherapy and chemokine-targeted CAR-T treatment [185]. This evidence concerns the gene CXCR1 and neoplasm.